Asthma: The Daily PANCE Blueprint
A 30-year-old man has had asthma for the past 8 years. His symptoms are frequently triggered by pollen and exercise. Over the past year, he has visited the emergency department twice for asthma exacerbations, each time requiring oral corticosteroids. He uses his albuterol inhaler about 3 times per week for symptom relief and experiences nighttime symptoms approximately once a week. According to the GINA guidelines, which of the following would be the most appropriate step in therapy to maintain remission between his asthmatic attacks?
A. As-needed low-dose ICS-formoterol (LABA)
B. Daily low-dose ICS-formoterol (LABA)
C. Medium-dose ICS-formoterol (LABA)
D. Add-on long-acting muscarinic antagonist (LAMA)
E. Oral prednisone
Answer and topic summary
The answer is B. Daily low-dose ICS-formoterol (LABA)
According to the GINA guidelines, the most appropriate step in therapy for this patient, given his symptoms and frequency of exacerbations, is daily low-dose ICS-formoterol (LABA). This recommendation corresponds to Step 3 of the GINA guidelines, which is suitable for patients who have symptoms most days, wake with asthma once a week or more, or have frequent use of a reliever inhaler.
Incorrect Answer Explanations:
- A. As-needed low-dose ICS-formoterol (LABA): This option corresponds to Step 1-2 of the GINA guidelines, which is for patients with less frequent symptoms (less than 4-5 days a week). The patient’s symptom frequency and nighttime awakenings suggest that more consistent control is needed.
- C. Medium-dose ICS-formoterol (LABA): Medium-dose ICS-formoterol (LABA) is recommended for patients in Step 4, who have daily symptoms or wake with asthma once a week or more and have low lung function. While the patient has frequent symptoms, his lung function status is not described as being low.
- D. Add-on long-acting muscarinic antagonist (LAMA): Adding a LAMA is recommended at Step 5 for patients who need additional control beyond ICS and LABA. This step is typically considered when medium-dose ICS-formoterol is insufficient, which is not indicated for this patient based on the current information.
- E. Oral prednisone: Oral prednisone is used for acute exacerbations and severe asthma cases. Long-term use of oral corticosteroids is associated with significant side effects and is not recommended for maintenance therapy due to the risk of systemic complications.
View blueprint lesson
Smarty PANCE Content Blueprint Review:
Covered under ⇒ PANCE Blueprint Pulmonary ⇒ ⇒
